Singulex Homepage2018-10-22T14:01:40+00:00

It’s time to take control of
Clostridium difficile infection (CDI).

False positives, high infection rates, and extended hospital stays all add up
to unnecessary stress and expense to your patients and institution.

Current testing methods are complicated and inconclusive

NAAT for Toxin Genes

Expensive and susceptible to false positives.1

EIA for Toxin

Susceptible to false negatives.1

EIA for GDH Antigen

Cannot distinguish between toxigenic and nontoxigenic strains.1

Multistep Algorithms

Reflex testing leads to diagnostic uncertainty.1

Confounding factors add to the complexity

Appropriate Specimen Submission

Adherence to guideline-recommended stool specimen submission can be difficult to control.

Laxative Use

It’s been shown that nearly 20% of hospitalized patients have used laxatives in the last 48 hours.2

Antibiotic Exposure

Asymptomatic carriers treated with antibiotics are at risk for true CDI.2

“There is an urgent need to educate physicians that molecular tests are not specific for CDI, even in the presence of symptoms, and patients with positive PCR results do not necessarily need treatment.”2

High sensitivity and specificity in a single test can help you to alleviate the burden of CDI.

Eliminate complicated

Reduce false positives and over-diagnoses

Decrease the need for infection control measures

Reduce staff

Improve antibiotic stewardship

Discover unprecedented sensitivity
for unprecedented insight into disease status

Powered by proprietary Single Molecule Counting technology, the Singulex Clarity® system delivers definitive, actionable results—fast.

Up to 100 times more sensitive
than conventional immunoassays

Stratify, monitor, and
rule disease in—and out

Fully automated, easy-to-use platform
Clinically actionable results
in under 35 minutes

Singulex is a true innovator in delivering unprecedented diagnostic sensitivity for exceptional insight to shift the care paradigm from reactive disease treatment to proactive health management.

1. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.

2. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175(11):1792-1801.